Managing Depression and Arrhythmia with Pharmacogenetics

Patient Profile:

• Age: 50 years old
• Gender: Female
• Medical History: Diagnosed with major depression and arrhythmia.

Clinical Presentation: The patient, a 50-year-old woman, was experiencing both cardiac arrhythmias and major depression. Her treatment regimen, prescribed independently by her psychologist and cardiologist, included medications targeting both conditions. Shortly after beginning her new medications, she reported several distressing symptoms such as nausea, vomiting, tachycardia, agitation, and sleep disturbances, which prompted further evaluation of her treatment approach.

Diagnostic Journey: Concerned about the possible interactions between her medications and her body’s ability to metabolize them, her healthcare providers recommended a consultation with a genetic counselor. The counselor suggested a metabolic pathway gene analysis with a focus on the cytochrome P450 enzymes, known for their role in drug metabolism.

Genetic Findings: The genetic testing highlighted significant insights into the patient’s pharmacogenetic profile. It revealed that she is a poor metabolizer of the CYP2D6 enzyme and an intermediate metabolizer of CYP2C19. These traits contribute to her body’s unusual response to the prescribed drugs, as these enzymes play critical roles in the metabolism of many medications used for treating depression and cardiac issues.